{"gene":"MDM2","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1997,"finding":"MDM2 interaction with p53 promotes proteasome-dependent degradation of p53, reducing p53 protein levels. Endogenous levels of MDM2 are sufficient to regulate p53 stability, and overexpression of MDM2 reduces endogenous p53 protein.","method":"Transfection/overexpression assays, proteasome inhibitor studies, endogenous protein level analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational finding replicated across many labs, established with direct functional experiments","pmids":["9153396"],"is_preprint":false},{"year":1995,"finding":"MDM2 physically interacts with the retinoblastoma protein pRB and inhibits pRB growth-regulatory function, demonstrating a p53-independent oncogenic mechanism.","method":"Co-immunoprecipitation, functional growth assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding and functional inhibition demonstrated, replicated in subsequent work","pmids":["7791904"],"is_preprint":false},{"year":2003,"finding":"MDM2 functions as the principal p53-specific E3 ubiquitin ligase in unstressed cells, constitutively monoubiquitinating p53 to mediate its degradation by nuclear and cytoplasmic proteasomes.","method":"In vitro ubiquitination assays, cell-based degradation assays","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1 / Strong — E3 ligase activity established by in vitro assay, widely replicated","pmids":["14707283"],"is_preprint":false},{"year":1999,"finding":"HDM2/MDM2 must shuttle between nucleus and cytoplasm to target p53 for degradation; MDM2 mutants lacking NLS (nuclear entry) or NES (nuclear export) individually, or in combination, fail to promote p53 degradation, establishing that MDM2 shuttles p53 from nucleus to cytoplasm for proteasomal degradation.","method":"Site-directed mutagenesis of NLS/NES, cotransfection in p53/mdm2 double-null cells, p53 protein level assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple NLS/NES mutants tested in defined genetic background with rigorous controls","pmids":["10077639"],"is_preprint":false},{"year":2003,"finding":"The ribosomal protein L11 binds HDM2 and inhibits its function, leading to stabilization and activation of p53. This interaction is enhanced by low-dose actinomycin D, linking ribosome biogenesis stress to p53 activation through HDM2 inhibition.","method":"Co-immunoprecipitation, functional p53 activity assays, actinomycin D treatment","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding and functional consequence demonstrated, replicated by multiple labs","pmids":["12842086"],"is_preprint":false},{"year":2004,"finding":"Nucleophosmin (NPM/B23) binds HDM2 and acts as a negative regulator of the p53-HDM2 interaction, protecting p53 from HDM2-mediated degradation. UV damage induces nucleoplasmic redistribution of NPM which facilitates this binding.","method":"RNAi knockdown, co-immunoprecipitation of endogenous and ectopic proteins, subcellular fractionation","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — RNAi plus co-IP of endogenous proteins, multiple orthogonal methods","pmids":["15144954"],"is_preprint":false},{"year":2004,"finding":"Ribosomal protein L23 interacts with HDM2 via the central acidic domain of HDM2 and an N-terminal domain of L23, forming a ternary complex with L11. L23 overexpression inhibits HDM2-induced p53 polyubiquitination and degradation, causing p53-dependent cell cycle arrest. L23 knockdown triggers nucleolar stress and p53 stabilization.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain mapping, in vivo ubiquitination assay, siRNA rescue, multiple orthogonal methods","pmids":["15314174"],"is_preprint":false},{"year":2003,"finding":"HdmX stimulates Hdm2-mediated ubiquitination of p53 in vitro, and also facilitates mutual ubiquitination between HdmX and Hdm2. Downregulation of HdmX in cells causes accumulation of both p53 and Hdm2, indicating that HdmX acts as a stimulator of Hdm2 E3 activity rather than an inhibitor.","method":"In vitro E3 ubiquitin ligase assay, siRNA knockdown, cell-based protein level analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of E3 activity plus in vivo siRNA validation, multiple orthogonal methods","pmids":["14507994"],"is_preprint":false},{"year":2001,"finding":"Hdmx stabilizes both p53 and Mdm2. Hdmx does not target p53 for degradation but stabilizes Mdm2 by inhibiting its self-ubiquitination, likely through heterodimerization of the RING fingers of Mdm2 and Hdmx.","method":"Transfection, protein stability assays, RING finger deletion mutants","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RING domain mutants used to define mechanism, single lab with two complementary approaches","pmids":["11606419"],"is_preprint":false},{"year":2000,"finding":"Hdmx stabilizes both p53 and Mdm2; the RING finger of Hdmx is necessary and sufficient for this stabilization, and likely involves hetero-oligomerization with the RING finger of Mdm2, inhibiting Mdm2 ubiquitin ligase activity. A trimeric Hdmx-Mdm2-p53 complex is proposed.","method":"Transfection, RING finger domain mutants, protein stability assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mutagenesis supports model, single lab","pmids":["10827196"],"is_preprint":false},{"year":2003,"finding":"MDM2 promotes MDMX ubiquitination and proteasomal degradation via its RING domain E3 ligase activity. ARF stimulates MDM2-mediated MDMX ubiquitination (while inhibiting MDM2 ubiquitination of p53) and both MDM2 and ARF levels are increased by DNA damage leading to MDMX downregulation.","method":"Ubiquitination assay, proteasome inhibitor experiments, ARF adenovirus expression, inducible MDM2 expression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct E3 ligase assay with domain mutants, multiple experimental conditions","pmids":["12860999"],"is_preprint":false},{"year":2001,"finding":"MDM2 can promote proteasomal degradation of p53 in both the nucleus and cytoplasm, provided they are co-compartmentalized. Nuclear export of p53 is not an absolute requirement for MDM2-mediated p53 degradation; ubiquitinated p53 accumulates in the nucleus when proteasome activity is inhibited. LMB inhibits MDM2-mediated ubiquitination of p53 by preventing MDM2 nuclear export.","method":"NES mutants of Mdm2 and p53, leptomycin B treatment, proteasome inhibition, subcellular fractionation","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple NES/NLS mutants, pharmacologic and genetic manipulation, orthogonal approaches","pmids":["11597128"],"is_preprint":false},{"year":2002,"finding":"Akt phosphorylates MDM2 at Ser186, enhancing MDM2-mediated ubiquitination and degradation of p53. Mutation of Ser186 to Ala renders MDM2 resistant to Akt-mediated enhancement of p53 ubiquitination and degradation.","method":"In vivo ubiquitination assay, site-directed mutagenesis (S186A), kinase assays, LY294002 inhibitor","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis plus ubiquitination assay and pharmacologic validation, single lab","pmids":["11923280"],"is_preprint":false},{"year":2002,"finding":"Small molecule inhibitors selectively block HDM2 E3 ligase-mediated ubiquitination of p53 without inhibiting HDM2 autoubiquitination, demonstrating that these two E3 activities of HDM2 can be pharmacologically separated. All three inhibitor classes were noncompetitive with respect to both substrates and bind at a common site on HDM2.","method":"In vitro E3 ubiquitin ligase assay, steady-state kinetic analysis, combinatorial inhibitor binding studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted E3 assay with multiple inhibitor classes and rigorous kinetic analysis","pmids":["12407176"],"is_preprint":false},{"year":2005,"finding":"Gankyrin binds MDM2/HDM2 and facilitates p53-MDM2 binding, increasing ubiquitylation and degradation of p53. Gankyrin also enhances MDM2 autoubiquitylation. Downregulation of gankyrin reduced amounts of MDM2 and p53 associated with the 26S proteasome.","method":"In vitro and in vivo ubiquitination assays, co-immunoprecipitation, siRNA knockdown, proteasome association assay","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro and in vivo ubiquitination assays plus siRNA knockdown, multiple orthogonal methods","pmids":["16023600"],"is_preprint":false},{"year":2005,"finding":"MDM2 stabilizes E2F1 protein by inhibiting its ubiquitination; MDM2 directly binds E2F1 and displaces SCF(SKP2), the E2F1 E3 ligase, thereby prolonging E2F1 half-life independent of p53 and pRB/p14ARF.","method":"Co-immunoprecipitation, ubiquitination assay, half-life measurement, MDM2 NLS deletion mutant","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and ubiquitination competition shown, single lab with multiple approaches","pmids":["16170383"],"is_preprint":false},{"year":2001,"finding":"An alternatively spliced HDM2 isoform (HDM2ALT1) lacking the p53-binding domain sequesters full-length HDM2 in the cytoplasm and inhibits HDM2-p53 interaction, thereby enhancing p53 transcriptional activity.","method":"Transient transfection, co-immunoprecipitation, subcellular localization, p53 transcriptional activity assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional and localization data, single lab, multiple assays","pmids":["11494132"],"is_preprint":false},{"year":2008,"finding":"MDM2 acts as an E3 ubiquitin ligase for FOXO transcription factors, inducing ATP-dependent (multi)mono-ubiquitination of FOXO in vitro and in vivo. Mdm2-FOXO co-immunoprecipitate and Mdm2-mediated ubiquitination regulates FOXO transcriptional activity.","method":"In vitro ubiquitination assay, co-immunoprecipitation, siRNA knockdown, in vivo co-expression","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution plus in vivo validation, single lab","pmids":["18665269"],"is_preprint":false},{"year":2003,"finding":"MDM2, together with ARF, regulates p53 sumoylation by targeting p53 to the nucleolus. MDM2 overexpression increases p53 SUMO-1 conjugation, further stimulated by ARF; nucleolar targeting of p53 is required for efficient sumoylation in an MDM2- and ARF-dependent manner.","method":"Co-immunoprecipitation, sumoylation assay, subcellular localization studies, MDM2 deletion mutants","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain deletion mutants and in vivo sumoylation assay, single lab","pmids":["12917636"],"is_preprint":false},{"year":2005,"finding":"MTBP (MDM2 binding protein) promotes MDM2-mediated ubiquitination and degradation of p53 and also MDM2 stabilization, both in an MDM2 RING finger-dependent manner. siRNA knockdown of endogenous MTBP reduces MDM2-mediated p53 regulation; UV (but not gamma-irradiation) destabilizes MTBP as part of the damage response.","method":"siRNA knockdown, ubiquitination assay, MDM2 RING mutants, UV/gamma irradiation","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA, RING domain dependency, and stress-specific regulation, single lab","pmids":["15632057"],"is_preprint":false},{"year":2008,"finding":"MDM2 interacts with Nbs1 (a component of the Mre11/Rad50/Nbs1 DNA repair complex) through a defined 31-amino-acid region; this interaction delays DNA double-strand break repair and phosphorylation of H2AX and ATM substrates, leading to chromosome instability and transformation independent of p53. Both Nbs1 and ATM (but not MDM2 ubiquitin ligase activity) are required for this effect.","method":"Co-immunoprecipitation, site-directed mutagenesis of MDM2 and Nbs1 binding domains, γH2AX foci analysis, chromosome break assay, transformation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reciprocal domain mutagenesis, multiple functional readouts, p53-null cells to isolate p53-independent mechanism","pmids":["18541670"],"is_preprint":false},{"year":2009,"finding":"HDM2 functions as a ubiquitin E3 ligase for Ku70, ubiquitinating and destabilizing Ku70 protein. Akt-mediated phosphorylation of HDM2 promotes its nuclear translocation, which inhibits cytosolic Ku70 degradation and thereby suppresses Bax-mediated apoptosis.","method":"Co-immunoprecipitation, ubiquitination assay, constitutively active/kinase-dead Akt, siRNA knockdown, subcellular fractionation","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and E3 activity shown, Akt dependence validated with kinase-dead mutant, single lab","pmids":["19247369"],"is_preprint":false},{"year":2004,"finding":"PTEN negatively regulates MDM2 transcription through the MDM2 P1 promoter via its lipid phosphatase activity, independent of p53. In Pten-null cells, MDM2 P1 promoter activity is up-regulated, increasing L-Mdm2 expression.","method":"Promoter reporter assay, Pten-null cell lines and prostate cancer tissues, lipid phosphatase-dead PTEN mutant","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter assay with phosphatase mutant and Pten-null genetic model, single lab","pmids":["15090541"],"is_preprint":false},{"year":2013,"finding":"Ribosomal protein L6 (RPL6) binds HDM2, suppresses its E3 ubiquitin ligase activity, and attenuates HDM2-mediated p53 polyubiquitination and degradation. RPL6 translocates from nucleolus to nucleoplasm under ribosomal stress, facilitating HDM2 binding. The HDM2-RPL6 interaction leads to HDM2-mediated RPL6 polyubiquitination and degradation, forming an autoregulatory feedback loop.","method":"Co-immunoprecipitation, ubiquitination assay, subcellular fractionation, actinomycin D treatment, siRNA knockdown","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding, E3 inhibition and reciprocal ubiquitination shown, single lab with multiple methods","pmids":["24174547"],"is_preprint":false},{"year":2013,"finding":"Aurora kinase A (AURKA) directly interacts with and phosphorylates HDM2 protein in vitro; AURKA overexpression enhances HDM2 protein level and HDM2-mediated p53 ubiquitination; AURKA inhibition decreases HDM2 and induces p53 activity.","method":"Dual co-immunoprecipitation, in vitro kinase assay with recombinant proteins, AURKA knockdown/overexpression, p53 ubiquitination assay","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with recombinant proteins plus in vivo co-IP, single lab","pmids":["24240108"],"is_preprint":false},{"year":2008,"finding":"RYBP (RING1- and YY1-binding protein) interacts with MDM2 and decreases MDM2-mediated p53 ubiquitination, leading to stabilization and increased p53 activity. RYBP is involved in the p53 DNA damage response.","method":"Co-immunoprecipitation, ubiquitination assay, cell cycle analysis, DNA damage assay","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and ubiquitination assay, single lab with two orthogonal methods","pmids":["19098711"],"is_preprint":false},{"year":2009,"finding":"MDM2 interacts with p53 mRNA and stimulates its translation; this RNA binding is mediated through the RING domain, which overlaps with the E3 ligase domain, such that the p53 mRNA-MDM2 interaction suppresses MDM2's ability to promote p53 polyubiquitination and degradation.","method":"RNA-protein interaction assay, p53 protein synthesis measurement, E3 ligase activity assay","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional RNA-binding and E3 activity competition demonstrated, mechanistic insight into RING domain dual function, single lab","pmids":["19106616"],"is_preprint":false},{"year":2005,"finding":"MDM2 interacts with the sarcomeric protein TCAP (telethonin/T-cap), co-localizes with it in the nucleus, and promotes its ubiquitin-independent proteasomal degradation. Elevated MDM2 alters TCAP subcellular localization, and p14ARF inhibits MDM2-mediated TCAP degradation.","method":"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, confocal microscopy, proteasome inhibitor experiments","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding assays and functional degradation, single lab, ubiquitin-independence noted","pmids":["16678796"],"is_preprint":false},{"year":2016,"finding":"MDM2 protein binds the IRES region of XIAP mRNA; this protein-RNA interaction results in MDM2 protein stabilization and enhanced XIAP translation. Small molecule inhibitors blocking MDM2-XIAP RNA interaction cause MDM2 degradation and p53 activation.","method":"Fluorescence polarization protein-RNA binding assay, HTS compound screen, MDM2 protein stability assay, XIAP expression analysis","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein-RNA interaction assay and functional consequence, single study","pmids":["27666947"],"is_preprint":false},{"year":2012,"finding":"MdmX converts Mdm2 from a mono-ubiquitination E3 ligase into a p53 polyubiquitination E3 ligase necessary for p53 proteasomal degradation through RING-RING domain interactions. While Mdm2 is the catalytic component, MdmX is both the activating component and a substrate of the Mdm2/MdmX holoenzyme.","method":"In vitro ubiquitination assay, RING domain mutants, knock-in mouse models","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with domain mutants and in vivo genetic (knock-in) validation","pmids":["22673503"],"is_preprint":false},{"year":2007,"finding":"HDM2 binds p73 and inhibits its function; Nutlin-3, by disrupting the HDM2-p73 interaction, increases p73 transcriptional activity, p73 protein half-life, and p73-dependent apoptosis in p53-null cells.","method":"Co-immunoprecipitation of endogenous proteins, p73 half-life assay, siRNA knockdown of p73, p73 target gene analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous co-IP, siRNA rescue, half-life measurement, single lab","pmids":["17700533"],"is_preprint":false},{"year":2017,"finding":"Mdm2 interacts with polycomb group (PcG) proteins, including EZH2 and RING1B; EZH2 recruits Mdm2 to target gene promoters where it enhances repressive chromatin modifications (H3K27me3 and H2AK119ub1), supporting gene repression and stem cell phenotype in a p53-independent manner.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, histone modification analysis, gene expression profiling","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus co-IP with multiple PcG partners, single lab","pmids":["27927750"],"is_preprint":false}],"current_model":"MDM2 is an E3 ubiquitin ligase and master negative regulator of p53 that constitutively monoubiquitinates p53 (converted to polyubiquitination in complex with MDMX/MDM4) to drive proteasomal degradation; it also directly blocks p53 transcriptional activity by binding its transactivation domain, shuttles p53 from nucleus to cytoplasm via its own NLS/NES, and is itself transcriptionally induced by p53, forming a negative feedback loop. MDM2 activity is regulated by phosphorylation (e.g., by Akt at Ser186 and AURKA) and by multiple binding partners including ribosomal proteins (L11, L23, L6), nucleophosmin (NPM), ARF, MTBP, RYBP, and gankyrin. Beyond p53, MDM2 ubiquitinates MDMX, FOXO transcription factors, Ku70, and TCAP, stabilizes E2F1 by blocking its ubiquitination, binds p73 to inhibit its function, inhibits DNA double-strand break repair by interacting with Nbs1, stimulates p53 mRNA translation via its RING domain, binds XIAP mRNA, and cooperates with polycomb complexes to repress chromatin in a p53-independent manner."},"narrative":{"mechanistic_narrative":"MDM2 is the principal negative regulator of the tumor suppressor p53, functioning as a p53-specific E3 ubiquitin ligase that constitutively monoubiquitinates p53 in unstressed cells to drive its proteasomal degradation [PMID:9153396, PMID:14707283]. Efficient degradation requires MDM2 to shuttle between nucleus and cytoplasm via its own NLS and NES, co-compartmentalizing with p53 so that ubiquitinated substrate is delivered to nuclear and cytoplasmic proteasomes [PMID:10077639, PMID:11597128]. Its E3 output is dictated by heterodimerization with MDMX/HdmX through reciprocal RING-RING interactions: MDMX stimulates MDM2 ligase activity and converts MDM2 from a monoubiquitination to a polyubiquitination enzyme, with MDMX itself serving as both activator and substrate of the holoenzyme [PMID:14507994, PMID:22673503, PMID:12860999]. MDM2 activity is tuned by phosphorylation — Akt at Ser186 and AURKA both enhance MDM2-mediated p53 ubiquitination [PMID:11923280, PMID:24240108] — and by an upstream PTEN-controlled transcriptional input that restrains MDM2 expression through the P1 promoter [PMID:15090541]. A major regulatory axis couples ribosome biogenesis and nucleolar stress to p53: ribosomal proteins L11, L23, and L6, together with nucleophosmin, bind MDM2 and inhibit its ligase activity to stabilize and activate p53, while additional partners such as gankyrin and MTBP promote, and RYBP inhibits, MDM2-driven p53 turnover [PMID:12842086, PMID:15144954, PMID:15314174, PMID:24174547, PMID:16023600, PMID:15632057, PMID:19098711]. Beyond p53, MDM2 ubiquitinates MDMX, FOXO factors, and Ku70, stabilizes E2F1 by displacing its SCF(SKP2) ligase, binds and inhibits p73, and delays DNA double-strand break repair through interaction with Nbs1 — establishing p53-independent oncogenic functions [PMID:12860999, PMID:18665269, PMID:19247369, PMID:16170383, PMID:17700533, PMID:18541670, PMID:7791904]. The RING domain also confers RNA-binding activity: MDM2 binds p53 mRNA to stimulate its translation and binds the XIAP IRES to enhance XIAP translation, with RNA engagement reciprocally suppressing its E3 ligase activity [PMID:19106616, PMID:27666947]. MDM2 further cooperates with polycomb proteins EZH2 and RING1B to enforce repressive chromatin marks at target promoters independently of p53 [PMID:27927750].","teleology":[{"year":1995,"claim":"Established that MDM2 has oncogenic activity beyond p53 by physically engaging and inactivating the retinoblastoma protein, broadening MDM2 from a p53 regulator to a multi-target growth controller.","evidence":"Co-immunoprecipitation and growth assays with pRB","pmids":["7791904"],"confidence":"High","gaps":["Domain of MDM2 mediating pRB binding not defined here","Physiological contexts where this dominates over p53 regulation unclear"]},{"year":1997,"claim":"Answered how MDM2 controls p53 abundance by showing the interaction promotes proteasome-dependent p53 degradation at endogenous MDM2 levels, defining the core feedback brake on p53.","evidence":"Overexpression and proteasome-inhibitor studies with endogenous protein readouts","pmids":["9153396"],"confidence":"High","gaps":["Did not establish MDM2 as the direct ligase versus an adaptor","Subcellular site of degradation not resolved"]},{"year":1999,"claim":"Determined that MDM2 must shuttle nucleocytoplasmically to degrade p53, linking its NLS/NES to substrate clearance.","evidence":"NLS/NES mutagenesis in p53/mdm2 double-null cells","pmids":["10077639"],"confidence":"High","gaps":["Whether export is strictly required was later contested (see 2001)"]},{"year":2001,"claim":"Refined the shuttling model, showing degradation can occur in either compartment once MDM2 and p53 co-localize, so nuclear export is facilitating rather than absolutely required.","evidence":"NES mutants, leptomycin B and proteasome inhibition with fractionation","pmids":["11597128"],"confidence":"High","gaps":["Relative contribution of nuclear versus cytoplasmic proteasomes in vivo not quantified"]},{"year":2001,"claim":"Identified MDMX/Hdmx as a RING-RING partner that stabilizes both MDM2 and p53 by inhibiting MDM2 self-ubiquitination, introducing the heterodimer as a key regulatory node.","evidence":"Transfection and RING-finger deletion mutant stability assays","pmids":["11606419","10827196"],"confidence":"Medium","gaps":["Single-lab models; reconciled only later with stimulatory role","Trimeric complex proposed but not structurally confirmed"]},{"year":2003,"claim":"Established MDM2 as the principal p53-specific E3 ligase that constitutively monoubiquitinates p53, defining the molecular activity behind p53 turnover.","evidence":"In vitro ubiquitination and cell-based degradation assays","pmids":["14707283"],"confidence":"High","gaps":["Mono- versus poly-ubiquitination determinants not yet resolved"]},{"year":2003,"claim":"Resolved MDMX's role as a stimulator rather than inhibitor of MDM2 E3 activity and a substrate of the complex, clarifying conflicting earlier stabilization data.","evidence":"In vitro E3 assays and siRNA knockdown","pmids":["14507994"],"confidence":"High","gaps":["Stimulatory versus stabilizing roles context-dependent and not fully reconciled"]},{"year":2003,"claim":"Showed MDM2 ubiquitinates MDMX itself, with ARF redirecting MDM2 activity from p53 toward MDMX, revealing reciprocal regulation within the MDM2/MDMX module.","evidence":"Ubiquitination assays with ARF expression and DNA damage","pmids":["12860999"],"confidence":"High","gaps":["Switch determinants controlling substrate choice not defined"]},{"year":2003,"claim":"Connected MDM2 to p53 sumoylation by nucleolar targeting, expanding its post-translational control of p53 beyond ubiquitination.","evidence":"In vivo sumoylation assay with MDM2 deletion mutants and ARF","pmids":["12917636"],"confidence":"Medium","gaps":["Functional consequence of p53 sumoylation here not established","Single lab"]},{"year":2002,"claim":"Demonstrated kinase control of MDM2: Akt phosphorylation at Ser186 enhances p53 ubiquitination, linking PI3K/Akt signaling to p53 suppression.","evidence":"S186A mutagenesis, kinase and ubiquitination assays, LY294002","pmids":["11923280"],"confidence":"High","gaps":["Mechanism by which Ser186 phosphorylation alters ligase activity unresolved"]},{"year":2002,"claim":"Showed MDM2's two E3 activities (p53 ubiquitination versus autoubiquitination) are pharmacologically separable, establishing the ligase as a druggable target.","evidence":"In vitro E3 assays with multiple noncompetitive inhibitor classes and kinetics","pmids":["12407176"],"confidence":"High","gaps":["Common inhibitor binding site not structurally mapped"]},{"year":2004,"claim":"Defined the nucleolar/ribosomal stress axis: L11, L23, and nucleophosmin bind MDM2 and inhibit its ligase to stabilize p53, coupling ribosome biogenesis surveillance to p53.","evidence":"Co-IP, domain mapping, ubiquitination and siRNA assays with actinomycin D/UV","pmids":["12842086","15144954","15314174"],"confidence":"High","gaps":["Hierarchy and stoichiometry among ribosomal protein partners unclear","Stress-specific selectivity not fully defined"]},{"year":2004,"claim":"Identified PTEN as a p53-independent transcriptional brake on MDM2 via the P1 promoter, placing MDM2 expression downstream of lipid-phosphatase signaling.","evidence":"Promoter reporter assays in Pten-null cells with phosphatase-dead mutant","pmids":["15090541"],"confidence":"Medium","gaps":["Intermediate transcription factors linking PTEN to P1 not identified","Single lab"]},{"year":2005,"claim":"Expanded the partner network with gankyrin and MTBP as positive regulators of MDM2-mediated p53 degradation, and an alternatively spliced isoform that sequesters MDM2 to activate p53.","evidence":"Co-IP, ubiquitination, siRNA, proteasome-association and localization assays","pmids":["16023600","15632057","11494132"],"confidence":"Medium","gaps":["Relative contributions in physiological settings unquantified","Mostly single-lab"]},{"year":2005,"claim":"Revealed p53-independent substrate range: MDM2 stabilizes E2F1 by displacing its ligase and promotes ubiquitin-independent degradation of TCAP.","evidence":"Co-IP, ubiquitination competition, half-life and proteasome inhibitor assays","pmids":["16170383","16678796"],"confidence":"Medium","gaps":["Physiological significance of TCAP and E2F1 regulation unclear","Single-lab findings"]},{"year":2007,"claim":"Showed MDM2 binds and inhibits the p53 family member p73, with Nutlin-3 relieving this to drive p73-dependent apoptosis in p53-null cells.","evidence":"Endogenous co-IP, half-life, siRNA and target-gene analysis","pmids":["17700533"],"confidence":"Medium","gaps":["Whether inhibition involves ubiquitination or binding alone not resolved"]},{"year":2008,"claim":"Established additional E3 substrates (FOXO factors) and a non-catalytic role in DNA repair, where MDM2-Nbs1 binding delays double-strand break repair and promotes transformation independent of ligase activity.","evidence":"In vitro/in vivo ubiquitination, reciprocal domain mutagenesis, γH2AX and chromosome break assays","pmids":["18665269","18541670"],"confidence":"High","gaps":["FOXO ubiquitination physiology single-lab","How MDM2 mechanistically delays repair at Nbs1 unresolved"]},{"year":2008,"claim":"Added RYBP as a negative regulator of MDM2-mediated p53 ubiquitination acting in the DNA damage response.","evidence":"Co-IP, ubiquitination, cell cycle and DNA damage assays","pmids":["19098711"],"confidence":"Medium","gaps":["Mechanism of ligase inhibition not defined","Single lab"]},{"year":2009,"claim":"Uncovered a dual function of the RING domain as an RNA-binding module: MDM2 binds p53 mRNA to stimulate translation, with RNA engagement suppressing its own E3 activity, and ubiquitinates Ku70 to suppress apoptosis under Akt control.","evidence":"RNA-protein interaction, translation and E3 activity assays; ubiquitination with Akt mutants","pmids":["19106616","19247369"],"confidence":"Medium","gaps":["RNA-binding versus catalytic switch quantitatively undefined","Single-lab studies"]},{"year":2012,"claim":"Defined the mono-to-poly ubiquitination switch mechanism: MDMX RING interaction converts MDM2 into a polyubiquitin ligase required for p53 degradation, with MDM2 catalytic and MDMX activating/substrate.","evidence":"In vitro ubiquitination with RING mutants and knock-in mouse models","pmids":["22673503"],"confidence":"High","gaps":["Structural basis of the chain-length switch not resolved"]},{"year":2013,"claim":"Extended kinase and ribosomal control: AURKA phosphorylates and stabilizes MDM2 to enhance p53 ubiquitination, while RPL6 inhibits MDM2 ligase activity in an autoregulatory ubiquitination loop.","evidence":"In vitro kinase, co-IP, ubiquitination and fractionation assays","pmids":["24240108","24174547"],"confidence":"Medium","gaps":["Both single-lab; integration with other ribosomal-protein partners unclear"]},{"year":2016,"claim":"Identified MDM2 as an XIAP IRES-binding protein that enhances XIAP translation and is itself stabilized by RNA binding, defining a druggable p53-independent pro-survival function.","evidence":"Fluorescence polarization RNA binding, HTS screen, stability and expression assays","pmids":["27666947"],"confidence":"Medium","gaps":["RNA-binding determinants on MDM2 not mapped here","Single study"]},{"year":2017,"claim":"Revealed a chromatin-repressive function: MDM2 is recruited by EZH2 to promoters where it augments H3K27me3 and H2AK119ub1 marks, supporting stemness independently of p53.","evidence":"Co-IP, ChIP, histone modification and expression profiling","pmids":["27927750"],"confidence":"Medium","gaps":["Whether MDM2 catalytic activity contributes to histone marks unclear","Single lab"]},{"year":null,"claim":"How MDM2's catalytic, RNA-binding, and chromatin-associated functions are coordinately switched between substrates and contexts, and the structural basis of its ubiquitin chain-length control, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated structural model of MDM2/MDMX holoenzyme substrate selection","Physiological weighting of p53-independent functions unquantified","Regulatory logic coupling RNA binding and E3 activity undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[2,7,10,17,21,29]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,10,17,21]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[26,28]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[15,30]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[31]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,11]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,11,21]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[18,23]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,21,30]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,10,17]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[15,31]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[31]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[4,5,6,23]}],"complexes":["MDM2/MDMX E3 ligase heterodimer","MDM2-L11-L23 ribosomal protein complex","polycomb repressive complex (with EZH2/RING1B)"],"partners":["TP53","MDM4","RPL11","RPL23","NPM1","NBN","EZH2","E2F1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q00987","full_name":"E3 ubiquitin-protein ligase Mdm2","aliases":["Double minute 2 protein","Hdm2","Oncoprotein Mdm2","RING-type E3 ubiquitin transferase Mdm2","p53-binding protein Mdm2"],"length_aa":491,"mass_kda":55.2,"function":"E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome (PubMed:29681526). Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also a component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation (PubMed:12821780, PubMed:15053880, PubMed:15195100, PubMed:15632057, PubMed:16337594, PubMed:17290220, PubMed:19098711, PubMed:19219073, PubMed:19837670, PubMed:19965871, PubMed:20173098, PubMed:20385133, PubMed:20858735, PubMed:22128911). Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells (By similarity). Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis (By similarity). Negatively regulates NDUFS1, leading to decreased mitochondrial respiration, marked oxidative stress, and commitment to the mitochondrial pathway of apoptosis (PubMed:30879903). Binds NDUFS1 leading to its cytosolic retention rather than mitochondrial localization resulting in decreased supercomplex assembly (interactions between complex I and complex III), decreased complex I activity, ROS production, and apoptosis (PubMed:30879903)","subcellular_location":"Nucleus, nucleoplasm; Cytoplasm; Nucleus, nucleolus; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q00987/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/MDM2","classification":"Common Essential","n_dependent_lines":549,"n_total_lines":1208,"dependency_fraction":0.4544701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MDM2","total_profiled":1310},"omim":[{"mim_id":"621041","title":"PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY B, MEMBER 3; PHLDB3","url":"https://www.omim.org/entry/621041"},{"mim_id":"620390","title":"HEAT REPEAT-CONTAINING PROTEIN 1; HEATR1","url":"https://www.omim.org/entry/620390"},{"mim_id":"619596","title":"OCIA DOMAIN-CONTAINING PROTEIN 1; OCIAD1","url":"https://www.omim.org/entry/619596"},{"mim_id":"619522","title":"NEURODEVELOPMENTAL-CRANIOFACIAL SYNDROME WITH VARIABLE RENAL AND CARDIAC ABNORMALITIES; NECRC","url":"https://www.omim.org/entry/619522"},{"mim_id":"618849","title":"BONE MARROW FAILURE SYNDROME 6; BMFS6","url":"https://www.omim.org/entry/618849"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Centriolar satellite","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MDM2"},"hgnc":{"alias_symbol":["HDM2","MGC5370"],"prev_symbol":[]},"alphafold":{"accession":"Q00987","domains":[{"cath_id":"1.10.245.10","chopping":"28-110","consensus_level":"high","plddt":95.3454,"start":28,"end":110},{"cath_id":"2.30.30.380","chopping":"297-329","consensus_level":"medium","plddt":87.7442,"start":297,"end":329},{"cath_id":"3.30.40.10","chopping":"433-488","consensus_level":"high","plddt":91.8087,"start":433,"end":488}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q00987","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q00987-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q00987-F1-predicted_aligned_error_v6.png","plddt_mean":62.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MDM2","jax_strain_url":"https://www.jax.org/strain/search?query=MDM2"},"sequence":{"accession":"Q00987","fasta_url":"https://rest.uniprot.org/uniprotkb/Q00987.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q00987/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q00987"}},"corpus_meta":[{"pmid":"9153396","id":"PMC_9153396","title":"Regulation of p53 stability by Mdm2.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9153396","citation_count":2903,"is_preprint":false},{"pmid":"9671804","id":"PMC_9671804","title":"The MDM2 gene amplification database.","date":"1998","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9671804","citation_count":827,"is_preprint":false},{"pmid":"14707283","id":"PMC_14707283","title":"The MDM2-p53 interaction.","date":"2003","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/14707283","citation_count":734,"is_preprint":false},{"pmid":"16455486","id":"PMC_16455486","title":"p53 ubiquitination: Mdm2 and beyond.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16455486","citation_count":733,"is_preprint":false},{"pmid":"7791904","id":"PMC_7791904","title":"Interaction between the retinoblastoma protein and the oncoprotein MDM2.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7791904","citation_count":560,"is_preprint":false},{"pmid":"12842086","id":"PMC_12842086","title":"Regulation of HDM2 activity by the ribosomal protein L11.","date":"2003","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12842086","citation_count":552,"is_preprint":false},{"pmid":"11923280","id":"PMC_11923280","title":"Akt enhances Mdm2-mediated ubiquitination and degradation of p53.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11923280","citation_count":501,"is_preprint":false},{"pmid":"10065155","id":"PMC_10065155","title":"Functions of the MDM2 oncoprotein.","date":"1999","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/10065155","citation_count":493,"is_preprint":false},{"pmid":"14707282","id":"PMC_14707282","title":"MDM2, an introduction.","date":"2003","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/14707282","citation_count":369,"is_preprint":false},{"pmid":"20172729","id":"PMC_20172729","title":"The p53 orchestra: Mdm2 and Mdmx set the tone.","date":"2010","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20172729","citation_count":366,"is_preprint":false},{"pmid":"8221695","id":"PMC_8221695","title":"Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.","date":"1993","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8221695","citation_count":362,"is_preprint":false},{"pmid":"15144954","id":"PMC_15144954","title":"Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation.","date":"2004","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/15144954","citation_count":355,"is_preprint":false},{"pmid":"25396320","id":"PMC_25396320","title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25396320","citation_count":353,"is_preprint":false},{"pmid":"23885265","id":"PMC_23885265","title":"The MDM2-p53 pathway revisited.","date":"2013","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/23885265","citation_count":321,"is_preprint":false},{"pmid":"15314174","id":"PMC_15314174","title":"Inhibition of HDM2 and activation of p53 by ribosomal protein L23.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15314174","citation_count":308,"is_preprint":false},{"pmid":"10077639","id":"PMC_10077639","title":"Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10077639","citation_count":298,"is_preprint":false},{"pmid":"14507994","id":"PMC_14507994","title":"HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14507994","citation_count":289,"is_preprint":false},{"pmid":"11790555","id":"PMC_11790555","title":"The p53 and Mdm2 families in cancer.","date":"2002","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/11790555","citation_count":236,"is_preprint":false},{"pmid":"9285554","id":"PMC_9285554","title":"Mdm2: keeping p53 under control.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9285554","citation_count":235,"is_preprint":false},{"pmid":"12860999","id":"PMC_12860999","title":"MDM2 promotes ubiquitination and degradation of MDMX.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12860999","citation_count":204,"is_preprint":false},{"pmid":"16023600","id":"PMC_16023600","title":"The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.","date":"2005","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/16023600","citation_count":194,"is_preprint":false},{"pmid":"11606419","id":"PMC_11606419","title":"Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.","date":"2001","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/11606419","citation_count":190,"is_preprint":false},{"pmid":"11960904","id":"PMC_11960904","title":"p53-Mdm2--the affair that never ends.","date":"2002","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11960904","citation_count":179,"is_preprint":false},{"pmid":"23262034","id":"PMC_23262034","title":"Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23262034","citation_count":162,"is_preprint":false},{"pmid":"17700533","id":"PMC_17700533","title":"HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17700533","citation_count":158,"is_preprint":false},{"pmid":"35831864","id":"PMC_35831864","title":"Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.","date":"2022","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35831864","citation_count":156,"is_preprint":false},{"pmid":"19147532","id":"PMC_19147532","title":"Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19147532","citation_count":149,"is_preprint":false},{"pmid":"14707286","id":"PMC_14707286","title":"p53-independent functions of MDM2.","date":"2003","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/14707286","citation_count":128,"is_preprint":false},{"pmid":"10827196","id":"PMC_10827196","title":"Hdmx stabilizes Mdm2 and p53.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10827196","citation_count":125,"is_preprint":false},{"pmid":"16170383","id":"PMC_16170383","title":"Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16170383","citation_count":123,"is_preprint":false},{"pmid":"11494132","id":"PMC_11494132","title":"An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11494132","citation_count":121,"is_preprint":false},{"pmid":"18665269","id":"PMC_18665269","title":"Mdm2 induces mono-ubiquitination of FOXO4.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18665269","citation_count":112,"is_preprint":false},{"pmid":"11597128","id":"PMC_11597128","title":"Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.","date":"2001","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11597128","citation_count":110,"is_preprint":false},{"pmid":"22410433","id":"PMC_22410433","title":"Regulation of p53: a collaboration between Mdm2 and Mdmx.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/22410433","citation_count":107,"is_preprint":false},{"pmid":"17526734","id":"PMC_17526734","title":"Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17526734","citation_count":107,"is_preprint":false},{"pmid":"11606406","id":"PMC_11606406","title":"HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11606406","citation_count":105,"is_preprint":false},{"pmid":"12917636","id":"PMC_12917636","title":"MDM2-ARF complex regulates p53 sumoylation.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12917636","citation_count":103,"is_preprint":false},{"pmid":"26482041","id":"PMC_26482041","title":"Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26482041","citation_count":103,"is_preprint":false},{"pmid":"21504625","id":"PMC_21504625","title":"Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.","date":"2011","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21504625","citation_count":98,"is_preprint":false},{"pmid":"9400998","id":"PMC_9400998","title":"Induction of Mdm2 and enhancement of cell survival by bFGF.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9400998","citation_count":96,"is_preprint":false},{"pmid":"28629371","id":"PMC_28629371","title":"Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28629371","citation_count":89,"is_preprint":false},{"pmid":"18541670","id":"PMC_18541670","title":"Mdm2 promotes genetic instability and transformation independent of p53.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18541670","citation_count":89,"is_preprint":false},{"pmid":"11353053","id":"PMC_11353053","title":"Abnormal expression of MDM2 in prostate carcinoma.","date":"2001","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/11353053","citation_count":88,"is_preprint":false},{"pmid":"26132471","id":"PMC_26132471","title":"Transcription factors that interact with p53 and Mdm2.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26132471","citation_count":87,"is_preprint":false},{"pmid":"7738717","id":"PMC_7738717","title":"MDM2 and CDK4 gene amplification in Ewing's sarcoma.","date":"1995","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7738717","citation_count":87,"is_preprint":false},{"pmid":"22673503","id":"PMC_22673503","title":"Mdm2 and MdmX partner to regulate p53.","date":"2012","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/22673503","citation_count":86,"is_preprint":false},{"pmid":"12407176","id":"PMC_12407176","title":"Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12407176","citation_count":86,"is_preprint":false},{"pmid":"15090541","id":"PMC_15090541","title":"PTEN regulates Mdm2 expression through the P1 promoter.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15090541","citation_count":85,"is_preprint":false},{"pmid":"11485818","id":"PMC_11485818","title":"MDM2: life without p53.","date":"2001","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/11485818","citation_count":84,"is_preprint":false},{"pmid":"25201198","id":"PMC_25201198","title":"p53-independent effects of Mdm2.","date":"2014","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25201198","citation_count":82,"is_preprint":false},{"pmid":"24141721","id":"PMC_24141721","title":"miR-661 downregulates both Mdm2 and Mdm4 to activate p53.","date":"2013","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24141721","citation_count":81,"is_preprint":false},{"pmid":"24096477","id":"PMC_24096477","title":"MDM2's social network.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24096477","citation_count":80,"is_preprint":false},{"pmid":"27927749","id":"PMC_27927749","title":"Modulation of the p53/MDM2 interplay by HAUSP inhibitors.","date":"2017","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27927749","citation_count":80,"is_preprint":false},{"pmid":"33799733","id":"PMC_33799733","title":"MDM2 Amplified Sarcomas: A Literature Review.","date":"2021","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33799733","citation_count":73,"is_preprint":false},{"pmid":"15254433","id":"PMC_15254433","title":"Mdmx and Mdm2: brothers in arms?","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15254433","citation_count":72,"is_preprint":false},{"pmid":"19098711","id":"PMC_19098711","title":"RYBP stabilizes p53 by modulating MDM2.","date":"2008","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/19098711","citation_count":72,"is_preprint":false},{"pmid":"25372739","id":"PMC_25372739","title":"The MDM2 gene family.","date":"2014","source":"Biomolecular concepts","url":"https://pubmed.ncbi.nlm.nih.gov/25372739","citation_count":71,"is_preprint":false},{"pmid":"23749457","id":"PMC_23749457","title":"Podocyte loss involves MDM2-driven mitotic catastrophe.","date":"2013","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23749457","citation_count":69,"is_preprint":false},{"pmid":"27666947","id":"PMC_27666947","title":"Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.","date":"2016","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/27666947","citation_count":69,"is_preprint":false},{"pmid":"9172803","id":"PMC_9172803","title":"Overexpression of the MDM2 oncogene in leukemia and lymphoma.","date":"1996","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9172803","citation_count":66,"is_preprint":false},{"pmid":"12713619","id":"PMC_12713619","title":"p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.","date":"2003","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/12713619","citation_count":64,"is_preprint":false},{"pmid":"15632057","id":"PMC_15632057","title":"Regulation of p53 and MDM2 activity by MTBP.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15632057","citation_count":62,"is_preprint":false},{"pmid":"19244108","id":"PMC_19244108","title":"Mdm2 affects genome stability independent of p53.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19244108","citation_count":61,"is_preprint":false},{"pmid":"24240108","id":"PMC_24240108","title":"HDM2 regulation by AURKA promotes cell survival in gastric cancer.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24240108","citation_count":60,"is_preprint":false},{"pmid":"18783169","id":"PMC_18783169","title":"Oscillations by the p53-Mdm2 feedback loop.","date":"2008","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/18783169","citation_count":59,"is_preprint":false},{"pmid":"18235222","id":"PMC_18235222","title":"Unlocking the Mdm2-p53 loop: ubiquitin is the key.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18235222","citation_count":59,"is_preprint":false},{"pmid":"30755442","id":"PMC_30755442","title":"MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30755442","citation_count":57,"is_preprint":false},{"pmid":"24174547","id":"PMC_24174547","title":"Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24174547","citation_count":56,"is_preprint":false},{"pmid":"15254398","id":"PMC_15254398","title":"Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response.","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15254398","citation_count":55,"is_preprint":false},{"pmid":"11351242","id":"PMC_11351242","title":"Expression of heparanase, Mdm2, and erbB2 in ovarian cancer.","date":"2001","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11351242","citation_count":55,"is_preprint":false},{"pmid":"19106616","id":"PMC_19106616","title":"The p53 mRNA-Mdm2 interaction.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19106616","citation_count":51,"is_preprint":false},{"pmid":"26119940","id":"PMC_26119940","title":"Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26119940","citation_count":51,"is_preprint":false},{"pmid":"9322885","id":"PMC_9322885","title":"The mdm2 proto-oncogene.","date":"1997","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9322885","citation_count":49,"is_preprint":false},{"pmid":"21949095","id":"PMC_21949095","title":"Mdm2 promotes systemic lupus erythematosus and lupus nephritis.","date":"2011","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/21949095","citation_count":48,"is_preprint":false},{"pmid":"36439412","id":"PMC_36439412","title":"Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36439412","citation_count":47,"is_preprint":false},{"pmid":"16243710","id":"PMC_16243710","title":"Mdm2 in growth signaling and cancer.","date":"2005","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/16243710","citation_count":46,"is_preprint":false},{"pmid":"17914240","id":"PMC_17914240","title":"The p53-MDM2 network: from oscillations to apoptosis.","date":"2007","source":"Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/17914240","citation_count":44,"is_preprint":false},{"pmid":"22134240","id":"PMC_22134240","title":"p53 regulation: teamwork between RING domains of Mdm2 and MdmX.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22134240","citation_count":42,"is_preprint":false},{"pmid":"25808808","id":"PMC_25808808","title":"Regulation of MDM2 Stability After DNA Damage.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25808808","citation_count":41,"is_preprint":false},{"pmid":"8660994","id":"PMC_8660994","title":"The organization and expression of the mdm2 gene.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8660994","citation_count":41,"is_preprint":false},{"pmid":"21051655","id":"PMC_21051655","title":"MDM2 as a modifier gene in retinoblastoma.","date":"2010","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/21051655","citation_count":41,"is_preprint":false},{"pmid":"19538162","id":"PMC_19538162","title":"Recent advances in validating MDM2 as a cancer target.","date":"2009","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19538162","citation_count":41,"is_preprint":false},{"pmid":"16624812","id":"PMC_16624812","title":"Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16624812","citation_count":40,"is_preprint":false},{"pmid":"19247369","id":"PMC_19247369","title":"Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization.","date":"2009","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19247369","citation_count":39,"is_preprint":false},{"pmid":"27932484","id":"PMC_27932484","title":"Role of Mdm2 and Mdmx in DNA repair.","date":"2017","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27932484","citation_count":38,"is_preprint":false},{"pmid":"18045074","id":"PMC_18045074","title":"Targeting MDM2 and MDMX in retinoblastoma.","date":"2007","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/18045074","citation_count":38,"is_preprint":false},{"pmid":"16678796","id":"PMC_16678796","title":"MDM2 interacts with and downregulates a sarcomeric protein, TCAP.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16678796","citation_count":38,"is_preprint":false},{"pmid":"19249672","id":"PMC_19249672","title":"p53 and MDM2: antagonists or partners in crime?","date":"2009","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/19249672","citation_count":37,"is_preprint":false},{"pmid":"15720189","id":"PMC_15720189","title":"Chemosensitization by antisense oligonucleotides targeting MDM2.","date":"2005","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/15720189","citation_count":37,"is_preprint":false},{"pmid":"9651526","id":"PMC_9651526","title":"MDM2 expression during mouse embryogenesis and the requirement of p53.","date":"1998","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/9651526","citation_count":36,"is_preprint":false},{"pmid":"17386256","id":"PMC_17386256","title":"Mdm2: p53's lifesaver?","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17386256","citation_count":35,"is_preprint":false},{"pmid":"23150765","id":"PMC_23150765","title":"Mdm2 in evolution.","date":"2012","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23150765","citation_count":35,"is_preprint":false},{"pmid":"16983334","id":"PMC_16983334","title":"Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16983334","citation_count":35,"is_preprint":false},{"pmid":"28092675","id":"PMC_28092675","title":"Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28092675","citation_count":35,"is_preprint":false},{"pmid":"27927750","id":"PMC_27927750","title":"Mdm2 as a chromatin modifier.","date":"2017","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27927750","citation_count":34,"is_preprint":false},{"pmid":"28077607","id":"PMC_28077607","title":"Anatomy of Mdm2 and Mdm4 in evolution.","date":"2017","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28077607","citation_count":34,"is_preprint":false},{"pmid":"23150752","id":"PMC_23150752","title":"Mdm2 and tumorigenesis: evolving theories and unsolved mysteries.","date":"2012","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23150752","citation_count":34,"is_preprint":false},{"pmid":"22650254","id":"PMC_22650254","title":"P53 mdm2 inhibitors.","date":"2012","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/22650254","citation_count":33,"is_preprint":false},{"pmid":"21295684","id":"PMC_21295684","title":"MDM2 and MDMX in cancer and development.","date":"2011","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21295684","citation_count":33,"is_preprint":false},{"pmid":"31331108","id":"PMC_31331108","title":"Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31331108","citation_count":33,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41736,"output_tokens":7251,"usd":0.116986,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16363,"output_tokens":6267,"usd":0.119245,"stage2_stop_reason":"end_turn"},"total_usd":0.236231,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"MDM2 interaction with p53 promotes proteasome-dependent degradation of p53, reducing p53 protein levels. Endogenous levels of MDM2 are sufficient to regulate p53 stability, and overexpression of MDM2 reduces endogenous p53 protein.\",\n      \"method\": \"Transfection/overexpression assays, proteasome inhibitor studies, endogenous protein level analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational finding replicated across many labs, established with direct functional experiments\",\n      \"pmids\": [\"9153396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MDM2 physically interacts with the retinoblastoma protein pRB and inhibits pRB growth-regulatory function, demonstrating a p53-independent oncogenic mechanism.\",\n      \"method\": \"Co-immunoprecipitation, functional growth assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding and functional inhibition demonstrated, replicated in subsequent work\",\n      \"pmids\": [\"7791904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MDM2 functions as the principal p53-specific E3 ubiquitin ligase in unstressed cells, constitutively monoubiquitinating p53 to mediate its degradation by nuclear and cytoplasmic proteasomes.\",\n      \"method\": \"In vitro ubiquitination assays, cell-based degradation assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — E3 ligase activity established by in vitro assay, widely replicated\",\n      \"pmids\": [\"14707283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HDM2/MDM2 must shuttle between nucleus and cytoplasm to target p53 for degradation; MDM2 mutants lacking NLS (nuclear entry) or NES (nuclear export) individually, or in combination, fail to promote p53 degradation, establishing that MDM2 shuttles p53 from nucleus to cytoplasm for proteasomal degradation.\",\n      \"method\": \"Site-directed mutagenesis of NLS/NES, cotransfection in p53/mdm2 double-null cells, p53 protein level assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple NLS/NES mutants tested in defined genetic background with rigorous controls\",\n      \"pmids\": [\"10077639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The ribosomal protein L11 binds HDM2 and inhibits its function, leading to stabilization and activation of p53. This interaction is enhanced by low-dose actinomycin D, linking ribosome biogenesis stress to p53 activation through HDM2 inhibition.\",\n      \"method\": \"Co-immunoprecipitation, functional p53 activity assays, actinomycin D treatment\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding and functional consequence demonstrated, replicated by multiple labs\",\n      \"pmids\": [\"12842086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Nucleophosmin (NPM/B23) binds HDM2 and acts as a negative regulator of the p53-HDM2 interaction, protecting p53 from HDM2-mediated degradation. UV damage induces nucleoplasmic redistribution of NPM which facilitates this binding.\",\n      \"method\": \"RNAi knockdown, co-immunoprecipitation of endogenous and ectopic proteins, subcellular fractionation\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — RNAi plus co-IP of endogenous proteins, multiple orthogonal methods\",\n      \"pmids\": [\"15144954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Ribosomal protein L23 interacts with HDM2 via the central acidic domain of HDM2 and an N-terminal domain of L23, forming a ternary complex with L11. L23 overexpression inhibits HDM2-induced p53 polyubiquitination and degradation, causing p53-dependent cell cycle arrest. L23 knockdown triggers nucleolar stress and p53 stabilization.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain mapping, in vivo ubiquitination assay, siRNA rescue, multiple orthogonal methods\",\n      \"pmids\": [\"15314174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HdmX stimulates Hdm2-mediated ubiquitination of p53 in vitro, and also facilitates mutual ubiquitination between HdmX and Hdm2. Downregulation of HdmX in cells causes accumulation of both p53 and Hdm2, indicating that HdmX acts as a stimulator of Hdm2 E3 activity rather than an inhibitor.\",\n      \"method\": \"In vitro E3 ubiquitin ligase assay, siRNA knockdown, cell-based protein level analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of E3 activity plus in vivo siRNA validation, multiple orthogonal methods\",\n      \"pmids\": [\"14507994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Hdmx stabilizes both p53 and Mdm2. Hdmx does not target p53 for degradation but stabilizes Mdm2 by inhibiting its self-ubiquitination, likely through heterodimerization of the RING fingers of Mdm2 and Hdmx.\",\n      \"method\": \"Transfection, protein stability assays, RING finger deletion mutants\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RING domain mutants used to define mechanism, single lab with two complementary approaches\",\n      \"pmids\": [\"11606419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Hdmx stabilizes both p53 and Mdm2; the RING finger of Hdmx is necessary and sufficient for this stabilization, and likely involves hetero-oligomerization with the RING finger of Mdm2, inhibiting Mdm2 ubiquitin ligase activity. A trimeric Hdmx-Mdm2-p53 complex is proposed.\",\n      \"method\": \"Transfection, RING finger domain mutants, protein stability assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mutagenesis supports model, single lab\",\n      \"pmids\": [\"10827196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MDM2 promotes MDMX ubiquitination and proteasomal degradation via its RING domain E3 ligase activity. ARF stimulates MDM2-mediated MDMX ubiquitination (while inhibiting MDM2 ubiquitination of p53) and both MDM2 and ARF levels are increased by DNA damage leading to MDMX downregulation.\",\n      \"method\": \"Ubiquitination assay, proteasome inhibitor experiments, ARF adenovirus expression, inducible MDM2 expression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct E3 ligase assay with domain mutants, multiple experimental conditions\",\n      \"pmids\": [\"12860999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MDM2 can promote proteasomal degradation of p53 in both the nucleus and cytoplasm, provided they are co-compartmentalized. Nuclear export of p53 is not an absolute requirement for MDM2-mediated p53 degradation; ubiquitinated p53 accumulates in the nucleus when proteasome activity is inhibited. LMB inhibits MDM2-mediated ubiquitination of p53 by preventing MDM2 nuclear export.\",\n      \"method\": \"NES mutants of Mdm2 and p53, leptomycin B treatment, proteasome inhibition, subcellular fractionation\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple NES/NLS mutants, pharmacologic and genetic manipulation, orthogonal approaches\",\n      \"pmids\": [\"11597128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Akt phosphorylates MDM2 at Ser186, enhancing MDM2-mediated ubiquitination and degradation of p53. Mutation of Ser186 to Ala renders MDM2 resistant to Akt-mediated enhancement of p53 ubiquitination and degradation.\",\n      \"method\": \"In vivo ubiquitination assay, site-directed mutagenesis (S186A), kinase assays, LY294002 inhibitor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis plus ubiquitination assay and pharmacologic validation, single lab\",\n      \"pmids\": [\"11923280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Small molecule inhibitors selectively block HDM2 E3 ligase-mediated ubiquitination of p53 without inhibiting HDM2 autoubiquitination, demonstrating that these two E3 activities of HDM2 can be pharmacologically separated. All three inhibitor classes were noncompetitive with respect to both substrates and bind at a common site on HDM2.\",\n      \"method\": \"In vitro E3 ubiquitin ligase assay, steady-state kinetic analysis, combinatorial inhibitor binding studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted E3 assay with multiple inhibitor classes and rigorous kinetic analysis\",\n      \"pmids\": [\"12407176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Gankyrin binds MDM2/HDM2 and facilitates p53-MDM2 binding, increasing ubiquitylation and degradation of p53. Gankyrin also enhances MDM2 autoubiquitylation. Downregulation of gankyrin reduced amounts of MDM2 and p53 associated with the 26S proteasome.\",\n      \"method\": \"In vitro and in vivo ubiquitination assays, co-immunoprecipitation, siRNA knockdown, proteasome association assay\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro and in vivo ubiquitination assays plus siRNA knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"16023600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MDM2 stabilizes E2F1 protein by inhibiting its ubiquitination; MDM2 directly binds E2F1 and displaces SCF(SKP2), the E2F1 E3 ligase, thereby prolonging E2F1 half-life independent of p53 and pRB/p14ARF.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, half-life measurement, MDM2 NLS deletion mutant\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and ubiquitination competition shown, single lab with multiple approaches\",\n      \"pmids\": [\"16170383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"An alternatively spliced HDM2 isoform (HDM2ALT1) lacking the p53-binding domain sequesters full-length HDM2 in the cytoplasm and inhibits HDM2-p53 interaction, thereby enhancing p53 transcriptional activity.\",\n      \"method\": \"Transient transfection, co-immunoprecipitation, subcellular localization, p53 transcriptional activity assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional and localization data, single lab, multiple assays\",\n      \"pmids\": [\"11494132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MDM2 acts as an E3 ubiquitin ligase for FOXO transcription factors, inducing ATP-dependent (multi)mono-ubiquitination of FOXO in vitro and in vivo. Mdm2-FOXO co-immunoprecipitate and Mdm2-mediated ubiquitination regulates FOXO transcriptional activity.\",\n      \"method\": \"In vitro ubiquitination assay, co-immunoprecipitation, siRNA knockdown, in vivo co-expression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution plus in vivo validation, single lab\",\n      \"pmids\": [\"18665269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MDM2, together with ARF, regulates p53 sumoylation by targeting p53 to the nucleolus. MDM2 overexpression increases p53 SUMO-1 conjugation, further stimulated by ARF; nucleolar targeting of p53 is required for efficient sumoylation in an MDM2- and ARF-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, sumoylation assay, subcellular localization studies, MDM2 deletion mutants\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain deletion mutants and in vivo sumoylation assay, single lab\",\n      \"pmids\": [\"12917636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MTBP (MDM2 binding protein) promotes MDM2-mediated ubiquitination and degradation of p53 and also MDM2 stabilization, both in an MDM2 RING finger-dependent manner. siRNA knockdown of endogenous MTBP reduces MDM2-mediated p53 regulation; UV (but not gamma-irradiation) destabilizes MTBP as part of the damage response.\",\n      \"method\": \"siRNA knockdown, ubiquitination assay, MDM2 RING mutants, UV/gamma irradiation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA, RING domain dependency, and stress-specific regulation, single lab\",\n      \"pmids\": [\"15632057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MDM2 interacts with Nbs1 (a component of the Mre11/Rad50/Nbs1 DNA repair complex) through a defined 31-amino-acid region; this interaction delays DNA double-strand break repair and phosphorylation of H2AX and ATM substrates, leading to chromosome instability and transformation independent of p53. Both Nbs1 and ATM (but not MDM2 ubiquitin ligase activity) are required for this effect.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis of MDM2 and Nbs1 binding domains, γH2AX foci analysis, chromosome break assay, transformation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reciprocal domain mutagenesis, multiple functional readouts, p53-null cells to isolate p53-independent mechanism\",\n      \"pmids\": [\"18541670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HDM2 functions as a ubiquitin E3 ligase for Ku70, ubiquitinating and destabilizing Ku70 protein. Akt-mediated phosphorylation of HDM2 promotes its nuclear translocation, which inhibits cytosolic Ku70 degradation and thereby suppresses Bax-mediated apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, constitutively active/kinase-dead Akt, siRNA knockdown, subcellular fractionation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and E3 activity shown, Akt dependence validated with kinase-dead mutant, single lab\",\n      \"pmids\": [\"19247369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PTEN negatively regulates MDM2 transcription through the MDM2 P1 promoter via its lipid phosphatase activity, independent of p53. In Pten-null cells, MDM2 P1 promoter activity is up-regulated, increasing L-Mdm2 expression.\",\n      \"method\": \"Promoter reporter assay, Pten-null cell lines and prostate cancer tissues, lipid phosphatase-dead PTEN mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter assay with phosphatase mutant and Pten-null genetic model, single lab\",\n      \"pmids\": [\"15090541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ribosomal protein L6 (RPL6) binds HDM2, suppresses its E3 ubiquitin ligase activity, and attenuates HDM2-mediated p53 polyubiquitination and degradation. RPL6 translocates from nucleolus to nucleoplasm under ribosomal stress, facilitating HDM2 binding. The HDM2-RPL6 interaction leads to HDM2-mediated RPL6 polyubiquitination and degradation, forming an autoregulatory feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, subcellular fractionation, actinomycin D treatment, siRNA knockdown\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding, E3 inhibition and reciprocal ubiquitination shown, single lab with multiple methods\",\n      \"pmids\": [\"24174547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Aurora kinase A (AURKA) directly interacts with and phosphorylates HDM2 protein in vitro; AURKA overexpression enhances HDM2 protein level and HDM2-mediated p53 ubiquitination; AURKA inhibition decreases HDM2 and induces p53 activity.\",\n      \"method\": \"Dual co-immunoprecipitation, in vitro kinase assay with recombinant proteins, AURKA knockdown/overexpression, p53 ubiquitination assay\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with recombinant proteins plus in vivo co-IP, single lab\",\n      \"pmids\": [\"24240108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RYBP (RING1- and YY1-binding protein) interacts with MDM2 and decreases MDM2-mediated p53 ubiquitination, leading to stabilization and increased p53 activity. RYBP is involved in the p53 DNA damage response.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, cell cycle analysis, DNA damage assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and ubiquitination assay, single lab with two orthogonal methods\",\n      \"pmids\": [\"19098711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MDM2 interacts with p53 mRNA and stimulates its translation; this RNA binding is mediated through the RING domain, which overlaps with the E3 ligase domain, such that the p53 mRNA-MDM2 interaction suppresses MDM2's ability to promote p53 polyubiquitination and degradation.\",\n      \"method\": \"RNA-protein interaction assay, p53 protein synthesis measurement, E3 ligase activity assay\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional RNA-binding and E3 activity competition demonstrated, mechanistic insight into RING domain dual function, single lab\",\n      \"pmids\": [\"19106616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MDM2 interacts with the sarcomeric protein TCAP (telethonin/T-cap), co-localizes with it in the nucleus, and promotes its ubiquitin-independent proteasomal degradation. Elevated MDM2 alters TCAP subcellular localization, and p14ARF inhibits MDM2-mediated TCAP degradation.\",\n      \"method\": \"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, confocal microscopy, proteasome inhibitor experiments\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding assays and functional degradation, single lab, ubiquitin-independence noted\",\n      \"pmids\": [\"16678796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MDM2 protein binds the IRES region of XIAP mRNA; this protein-RNA interaction results in MDM2 protein stabilization and enhanced XIAP translation. Small molecule inhibitors blocking MDM2-XIAP RNA interaction cause MDM2 degradation and p53 activation.\",\n      \"method\": \"Fluorescence polarization protein-RNA binding assay, HTS compound screen, MDM2 protein stability assay, XIAP expression analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein-RNA interaction assay and functional consequence, single study\",\n      \"pmids\": [\"27666947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MdmX converts Mdm2 from a mono-ubiquitination E3 ligase into a p53 polyubiquitination E3 ligase necessary for p53 proteasomal degradation through RING-RING domain interactions. While Mdm2 is the catalytic component, MdmX is both the activating component and a substrate of the Mdm2/MdmX holoenzyme.\",\n      \"method\": \"In vitro ubiquitination assay, RING domain mutants, knock-in mouse models\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with domain mutants and in vivo genetic (knock-in) validation\",\n      \"pmids\": [\"22673503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HDM2 binds p73 and inhibits its function; Nutlin-3, by disrupting the HDM2-p73 interaction, increases p73 transcriptional activity, p73 protein half-life, and p73-dependent apoptosis in p53-null cells.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, p73 half-life assay, siRNA knockdown of p73, p73 target gene analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous co-IP, siRNA rescue, half-life measurement, single lab\",\n      \"pmids\": [\"17700533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Mdm2 interacts with polycomb group (PcG) proteins, including EZH2 and RING1B; EZH2 recruits Mdm2 to target gene promoters where it enhances repressive chromatin modifications (H3K27me3 and H2AK119ub1), supporting gene repression and stem cell phenotype in a p53-independent manner.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, histone modification analysis, gene expression profiling\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus co-IP with multiple PcG partners, single lab\",\n      \"pmids\": [\"27927750\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MDM2 is an E3 ubiquitin ligase and master negative regulator of p53 that constitutively monoubiquitinates p53 (converted to polyubiquitination in complex with MDMX/MDM4) to drive proteasomal degradation; it also directly blocks p53 transcriptional activity by binding its transactivation domain, shuttles p53 from nucleus to cytoplasm via its own NLS/NES, and is itself transcriptionally induced by p53, forming a negative feedback loop. MDM2 activity is regulated by phosphorylation (e.g., by Akt at Ser186 and AURKA) and by multiple binding partners including ribosomal proteins (L11, L23, L6), nucleophosmin (NPM), ARF, MTBP, RYBP, and gankyrin. Beyond p53, MDM2 ubiquitinates MDMX, FOXO transcription factors, Ku70, and TCAP, stabilizes E2F1 by blocking its ubiquitination, binds p73 to inhibit its function, inhibits DNA double-strand break repair by interacting with Nbs1, stimulates p53 mRNA translation via its RING domain, binds XIAP mRNA, and cooperates with polycomb complexes to repress chromatin in a p53-independent manner.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MDM2 is the principal negative regulator of the tumor suppressor p53, functioning as a p53-specific E3 ubiquitin ligase that constitutively monoubiquitinates p53 in unstressed cells to drive its proteasomal degradation [#0, #2]. Efficient degradation requires MDM2 to shuttle between nucleus and cytoplasm via its own NLS and NES, co-compartmentalizing with p53 so that ubiquitinated substrate is delivered to nuclear and cytoplasmic proteasomes [#3, #11]. Its E3 output is dictated by heterodimerization with MDMX/HdmX through reciprocal RING-RING interactions: MDMX stimulates MDM2 ligase activity and converts MDM2 from a monoubiquitination to a polyubiquitination enzyme, with MDMX itself serving as both activator and substrate of the holoenzyme [#7, #29, #10]. MDM2 activity is tuned by phosphorylation — Akt at Ser186 and AURKA both enhance MDM2-mediated p53 ubiquitination [#12, #24] — and by an upstream PTEN-controlled transcriptional input that restrains MDM2 expression through the P1 promoter [#22]. A major regulatory axis couples ribosome biogenesis and nucleolar stress to p53: ribosomal proteins L11, L23, and L6, together with nucleophosmin, bind MDM2 and inhibit its ligase activity to stabilize and activate p53, while additional partners such as gankyrin and MTBP promote, and RYBP inhibits, MDM2-driven p53 turnover [#4, #5, #6, #23, #14, #19, #25]. Beyond p53, MDM2 ubiquitinates MDMX, FOXO factors, and Ku70, stabilizes E2F1 by displacing its SCF(SKP2) ligase, binds and inhibits p73, and delays DNA double-strand break repair through interaction with Nbs1 — establishing p53-independent oncogenic functions [#10, #17, #21, #15, #30, #20, #1]. The RING domain also confers RNA-binding activity: MDM2 binds p53 mRNA to stimulate its translation and binds the XIAP IRES to enhance XIAP translation, with RNA engagement reciprocally suppressing its E3 ligase activity [#26, #28]. MDM2 further cooperates with polycomb proteins EZH2 and RING1B to enforce repressive chromatin marks at target promoters independently of p53 [#31].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that MDM2 has oncogenic activity beyond p53 by physically engaging and inactivating the retinoblastoma protein, broadening MDM2 from a p53 regulator to a multi-target growth controller.\",\n      \"evidence\": \"Co-immunoprecipitation and growth assays with pRB\",\n      \"pmids\": [\"7791904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain of MDM2 mediating pRB binding not defined here\", \"Physiological contexts where this dominates over p53 regulation unclear\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Answered how MDM2 controls p53 abundance by showing the interaction promotes proteasome-dependent p53 degradation at endogenous MDM2 levels, defining the core feedback brake on p53.\",\n      \"evidence\": \"Overexpression and proteasome-inhibitor studies with endogenous protein readouts\",\n      \"pmids\": [\"9153396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish MDM2 as the direct ligase versus an adaptor\", \"Subcellular site of degradation not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Determined that MDM2 must shuttle nucleocytoplasmically to degrade p53, linking its NLS/NES to substrate clearance.\",\n      \"evidence\": \"NLS/NES mutagenesis in p53/mdm2 double-null cells\",\n      \"pmids\": [\"10077639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether export is strictly required was later contested (see 2001)\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Refined the shuttling model, showing degradation can occur in either compartment once MDM2 and p53 co-localize, so nuclear export is facilitating rather than absolutely required.\",\n      \"evidence\": \"NES mutants, leptomycin B and proteasome inhibition with fractionation\",\n      \"pmids\": [\"11597128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of nuclear versus cytoplasmic proteasomes in vivo not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified MDMX/Hdmx as a RING-RING partner that stabilizes both MDM2 and p53 by inhibiting MDM2 self-ubiquitination, introducing the heterodimer as a key regulatory node.\",\n      \"evidence\": \"Transfection and RING-finger deletion mutant stability assays\",\n      \"pmids\": [\"11606419\", \"10827196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab models; reconciled only later with stimulatory role\", \"Trimeric complex proposed but not structurally confirmed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Established MDM2 as the principal p53-specific E3 ligase that constitutively monoubiquitinates p53, defining the molecular activity behind p53 turnover.\",\n      \"evidence\": \"In vitro ubiquitination and cell-based degradation assays\",\n      \"pmids\": [\"14707283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mono- versus poly-ubiquitination determinants not yet resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved MDMX's role as a stimulator rather than inhibitor of MDM2 E3 activity and a substrate of the complex, clarifying conflicting earlier stabilization data.\",\n      \"evidence\": \"In vitro E3 assays and siRNA knockdown\",\n      \"pmids\": [\"14507994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stimulatory versus stabilizing roles context-dependent and not fully reconciled\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed MDM2 ubiquitinates MDMX itself, with ARF redirecting MDM2 activity from p53 toward MDMX, revealing reciprocal regulation within the MDM2/MDMX module.\",\n      \"evidence\": \"Ubiquitination assays with ARF expression and DNA damage\",\n      \"pmids\": [\"12860999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch determinants controlling substrate choice not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected MDM2 to p53 sumoylation by nucleolar targeting, expanding its post-translational control of p53 beyond ubiquitination.\",\n      \"evidence\": \"In vivo sumoylation assay with MDM2 deletion mutants and ARF\",\n      \"pmids\": [\"12917636\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of p53 sumoylation here not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated kinase control of MDM2: Akt phosphorylation at Ser186 enhances p53 ubiquitination, linking PI3K/Akt signaling to p53 suppression.\",\n      \"evidence\": \"S186A mutagenesis, kinase and ubiquitination assays, LY294002\",\n      \"pmids\": [\"11923280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Ser186 phosphorylation alters ligase activity unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed MDM2's two E3 activities (p53 ubiquitination versus autoubiquitination) are pharmacologically separable, establishing the ligase as a druggable target.\",\n      \"evidence\": \"In vitro E3 assays with multiple noncompetitive inhibitor classes and kinetics\",\n      \"pmids\": [\"12407176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Common inhibitor binding site not structurally mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the nucleolar/ribosomal stress axis: L11, L23, and nucleophosmin bind MDM2 and inhibit its ligase to stabilize p53, coupling ribosome biogenesis surveillance to p53.\",\n      \"evidence\": \"Co-IP, domain mapping, ubiquitination and siRNA assays with actinomycin D/UV\",\n      \"pmids\": [\"12842086\", \"15144954\", \"15314174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy and stoichiometry among ribosomal protein partners unclear\", \"Stress-specific selectivity not fully defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified PTEN as a p53-independent transcriptional brake on MDM2 via the P1 promoter, placing MDM2 expression downstream of lipid-phosphatase signaling.\",\n      \"evidence\": \"Promoter reporter assays in Pten-null cells with phosphatase-dead mutant\",\n      \"pmids\": [\"15090541\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Intermediate transcription factors linking PTEN to P1 not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Expanded the partner network with gankyrin and MTBP as positive regulators of MDM2-mediated p53 degradation, and an alternatively spliced isoform that sequesters MDM2 to activate p53.\",\n      \"evidence\": \"Co-IP, ubiquitination, siRNA, proteasome-association and localization assays\",\n      \"pmids\": [\"16023600\", \"15632057\", \"11494132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contributions in physiological settings unquantified\", \"Mostly single-lab\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed p53-independent substrate range: MDM2 stabilizes E2F1 by displacing its ligase and promotes ubiquitin-independent degradation of TCAP.\",\n      \"evidence\": \"Co-IP, ubiquitination competition, half-life and proteasome inhibitor assays\",\n      \"pmids\": [\"16170383\", \"16678796\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological significance of TCAP and E2F1 regulation unclear\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed MDM2 binds and inhibits the p53 family member p73, with Nutlin-3 relieving this to drive p73-dependent apoptosis in p53-null cells.\",\n      \"evidence\": \"Endogenous co-IP, half-life, siRNA and target-gene analysis\",\n      \"pmids\": [\"17700533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether inhibition involves ubiquitination or binding alone not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established additional E3 substrates (FOXO factors) and a non-catalytic role in DNA repair, where MDM2-Nbs1 binding delays double-strand break repair and promotes transformation independent of ligase activity.\",\n      \"evidence\": \"In vitro/in vivo ubiquitination, reciprocal domain mutagenesis, γH2AX and chromosome break assays\",\n      \"pmids\": [\"18665269\", \"18541670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FOXO ubiquitination physiology single-lab\", \"How MDM2 mechanistically delays repair at Nbs1 unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Added RYBP as a negative regulator of MDM2-mediated p53 ubiquitination acting in the DNA damage response.\",\n      \"evidence\": \"Co-IP, ubiquitination, cell cycle and DNA damage assays\",\n      \"pmids\": [\"19098711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of ligase inhibition not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Uncovered a dual function of the RING domain as an RNA-binding module: MDM2 binds p53 mRNA to stimulate translation, with RNA engagement suppressing its own E3 activity, and ubiquitinates Ku70 to suppress apoptosis under Akt control.\",\n      \"evidence\": \"RNA-protein interaction, translation and E3 activity assays; ubiquitination with Akt mutants\",\n      \"pmids\": [\"19106616\", \"19247369\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RNA-binding versus catalytic switch quantitatively undefined\", \"Single-lab studies\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the mono-to-poly ubiquitination switch mechanism: MDMX RING interaction converts MDM2 into a polyubiquitin ligase required for p53 degradation, with MDM2 catalytic and MDMX activating/substrate.\",\n      \"evidence\": \"In vitro ubiquitination with RING mutants and knock-in mouse models\",\n      \"pmids\": [\"22673503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the chain-length switch not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended kinase and ribosomal control: AURKA phosphorylates and stabilizes MDM2 to enhance p53 ubiquitination, while RPL6 inhibits MDM2 ligase activity in an autoregulatory ubiquitination loop.\",\n      \"evidence\": \"In vitro kinase, co-IP, ubiquitination and fractionation assays\",\n      \"pmids\": [\"24240108\", \"24174547\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Both single-lab; integration with other ribosomal-protein partners unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified MDM2 as an XIAP IRES-binding protein that enhances XIAP translation and is itself stabilized by RNA binding, defining a druggable p53-independent pro-survival function.\",\n      \"evidence\": \"Fluorescence polarization RNA binding, HTS screen, stability and expression assays\",\n      \"pmids\": [\"27666947\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RNA-binding determinants on MDM2 not mapped here\", \"Single study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a chromatin-repressive function: MDM2 is recruited by EZH2 to promoters where it augments H3K27me3 and H2AK119ub1 marks, supporting stemness independently of p53.\",\n      \"evidence\": \"Co-IP, ChIP, histone modification and expression profiling\",\n      \"pmids\": [\"27927750\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MDM2 catalytic activity contributes to histone marks unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MDM2's catalytic, RNA-binding, and chromatin-associated functions are coordinately switched between substrates and contexts, and the structural basis of its ubiquitin chain-length control, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated structural model of MDM2/MDMX holoenzyme substrate selection\", \"Physiological weighting of p53-independent functions unquantified\", \"Regulatory logic coupling RNA binding and E3 activity undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [2, 7, 10, 17, 21, 29]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 10, 17, 21]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [26, 28]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [15, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 11]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 11, 21]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [18, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 21, 30]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 10, 17]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [15, 31]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [31]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [4, 5, 6, 23]}\n    ],\n    \"complexes\": [\n      \"MDM2/MDMX E3 ligase heterodimer\",\n      \"MDM2-L11-L23 ribosomal protein complex\",\n      \"polycomb repressive complex (with EZH2/RING1B)\"\n    ],\n    \"partners\": [\n      \"TP53\",\n      \"MDM4\",\n      \"RPL11\",\n      \"RPL23\",\n      \"NPM1\",\n      \"NBN\",\n      \"EZH2\",\n      \"E2F1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}